All Posts Tagged With: "REGN"
(BAC) Company News for September 12, 2011 – Corporate Summary
• Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA) posted second quarter 2011 earnings of $0.38 per share, which surpassed the Zacks Consensus Estimate of $0.32
12Sep2011 | vitalstocks | 0 comments | Continued(BAC) Company News for August 29, 2011 – Corporate Summary
• According to reports, Bank of America Corporation (NYSE:BAC) has planned to sell at least half of its 10% stake in China Construction Bank
29Aug2011 | vitalstocks | 0 comments | Continued(REGN) Regeneron Pharmaceuticals Gets Mixed Data for REGN88
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi Aventis (SNY) recently announced data from two mid-stage studies of their pipeline...
(REGN) Bayer Seeks Eylea Approval in Japan
Germany’s Bayer (BAYRY) recently submitted an application to the Japanese Ministry of Health, Labor and Welfare (MHLW) seeking approval to market its eye treatment VEGF (vascular endothelial growth factor)...
(REGN) Regeneron Pharmaceuticals Wins Unanious FDA Panel Approval
Recently, the Dermatologic and Ophthalmic Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and unanimously recommended the US approval of Regeneron Pharmaceuticals Inc.’s (
21Jun2011 | vitalstocks | 0 comments | Continued(AFFX) Company News for June 03, 2011 – Corporate Summary
• Joy Global Inc. (NASDAQ:JOYG) posted Q2 EPS of $1.52, higher than the Zacks Consensus Estimate of $1.35 per share. Revenue for the quarter grew 19% to $1.06 billion, beating the Zacks Consensus Estimate of $1.038...
(ADTN) Company News for April 14, 2011 – Corporate Summary
• ADTRAN, Inc. (NASDAQ:ADTN) reported Q1 EPS of $0.52, ahead of the Zacks Consensus Estimate for $0.47 per share. Revenue for the quarter increased 30% year-over-year to $165.52 million, beating the Zacks Consensus Estimate...
(REGN) Regeneron Pharmaceuticals Quarterly Loss Wider than Expected
Regeneron Pharmaceuticals Inc.‘s (REGN) third quarter 2010 net loss of 41 cents per share was wider than the Zacks Consensus Estimate of a net loss of 34 cents. The company suffered a loss of 1 cent...
(RDEA) Ardea Biosciences Analyst Maintains Neutral Rating
We are maintaining our Neutral recommendation on Ardea Biosciences Inc. (RDEA) with a target price of $20.
Ardea Biosciences, headquartered in San Diego, CA, focuses on the discovery and development...
(REGN) Regeneron Pharmaceuticals’ Quarterly Loss Narrower than Expected
Regeneron Pharmaceuticals Inc.’s (REGN) second-quarter 2010 net loss of $25.5 million, or 31 cents per share, was narrower than the Zacks Consensus Estimate of a net loss of 38 cents. The company suffered...
(SNY) Sanofi-Aventis Announces Agreement to Acquire TargaGen
Sanofi-Aventis (SNY) continues to work on expanding its oncology portfolio with the company recently entering into an agreement to acquire TargaGen Inc. TargaGen, a privately-held US biopharmaceutical company,...
(REGN) Regeneron Pharmaceuticals Reports Narrower-Than-Forecasted Loss
Regeneron Pharmaceuticals Inc.’s (REGN) first-quarter loss of $30.5 million, or 38 cents per share, was narrower than the Zacks Consensus Estimate of a loss of 49 cents. The company suffered a loss of $15.4...
(REGN) Regeneron Pharmaceutical’s First Quarter Earnings Loss Narrower
Regeneron Pharmaceuticals Inc.’s (REGN) first-quarter loss of $30.5 million, or 38 cents per share, was narrower than the Zacks Consensus Estimate of a loss of 49 cents. The company suffered a loss of $15.4...
(PTIE) Financial Tides Positions – The Long and Short of it – February 16,2010
Each day I go on Barchart and sort the new high and new low list for frequency. I then take the top 10 highs and the top 10 lows and do additional screening. I’ll list here those that pass and might be good additions to your portfolio. Use this list as a starting...
(REGN) Regeneron Pharmaceuticals to Expand Research Positions
Regeneron Pharmaceuticals Inc. (REGN) announced recently that is investing $40 million, which will result in the creation of up to 100 jobs in East Greenbush facility in Rensselaer County, coupled with another...
(SNY) Sanofi-Aventis Expands Regeneron Pharmaceuticals Agreement
Sanofi-Aventis (SNY) recently extended and expanded its antibody collaboration with biopharmaceutical company, Regeneron Pharmaceuticals, Inc. (
25Nov2009 | vitalstocks | 0 comments | Continued(REGN) Regeneron Pharmaceuticals Enrolls for Studies
Last week, Regeneron Pharmaceuticals, Inc. (REGN) announced the completion of enrollment in two late stage studies of its VEGF (vascular endothelial growth factor) trap-eye treatment for age-related macular degeneration (wet AMD), a leading cause of blindness...